Kumar Manoj, Pahuja Sangeeta, Khare Prashant, Kumar Anoop
National Institute of Biologicals, Noida 201309, India.
Department of Immunohaematology and Blood Transfusion, Lady Hardinge Medical College and Associated Hospitals, New Delhi 110001, India.
Diagnostics (Basel). 2023 Jan 19;13(3):368. doi: 10.3390/diagnostics13030368.
It is estimated that approximately 260 million people worldwide are infected with the hepatitis B virus (HBV), which is one of the leading causes of liver disease and liver cancer throughout the world. Compared with developed countries, low-income and middle-income countries have limited access to resources and advanced technologies that require highly specialized staff for HBV diagnosis. In spite of the heavy burden caused by hepatitis B virus, 90% of people are still undiagnosed. The World Health Organization (WHO) goal of eliminating hepatitis B by 2030 seems very difficult to achieve due to the existing diagnostic infrastructure in low-resource regions. The majority of diagnostic laboratories still use hepatitis B surface antigen (HBsAg)-based tests. WHO's elimination plan is at risk of derailment due to phases like the window period, immune control, and occult HBV infection (OBI) not being detected by standard tests. Here, in this article, we are focusing on various diagnostic platforms for the better diagnosis of HBV. The aim of the elimination of HBV can only be achieved by detecting all phases of HBV infection, which can be executed by a combined approach of using new marker assays along with advanced pretesting and testing methods.
据估计，全球约有2.6亿人感染了乙肝病毒（HBV），该病毒是全球肝病和肝癌的主要病因之一。与发达国家相比，低收入和中等收入国家获取资源和先进技术的机会有限，而这些资源和技术需要高度专业化的人员进行HBV诊断。尽管乙肝病毒造成了沉重负担，但仍有90%的人未被诊断出来。由于资源匮乏地区现有的诊断基础设施，世界卫生组织（WHO）到2030年消除乙肝的目标似乎很难实现。大多数诊断实验室仍使用基于乙肝表面抗原（HBsAg）的检测方法。由于窗口期、免疫控制和隐匿性HBV感染（OBI）等阶段无法通过标准检测发现，WHO的消除计划有脱轨的风险。在此，在本文中，我们专注于各种诊断平台以更好地诊断HBV。只有通过检测HBV感染的所有阶段，才能实现消除HBV的目标，这可以通过结合使用新的标志物检测方法以及先进的检测前和检测方法来实现。
